Recursion Pharmaceuticals (RXRX) said Sunday early results from a phase 1/2 trial of its drug REC-4881 for Familial Adenomatous Polyposis showed a median reduction in polyp burden of 43% after 13 weeks among six patients who were evaluated.

The company said five patients saw polyp reductions between 31% and 82%, while one experienced a sharp increase compared to 20% to 30% reductions in other drugs over six months.

Three patients also showed improvement in the Spigelman stage, while one worsened and two had mixed or unclear results.